A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1748-717X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer ; volume:14 ; number:1 ; day:2 ; month:9 ; year:2019 ; pages:1-6 ; date:12.2019
Radiation oncology ; 14, Heft 1 (2.9.2019), 1-6, 12.2019
- Creator
-
Kainuma, Takuro
Kawakami, Shogo
Tsumura, Hideyasu
Satoh, Takefumi
Tabata, Ken-ichi
Iwamura, Masatsugu
Hayakawa, Kazushige
Ishiyama, Hiromichi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13014-019-1369-y
- URN
-
urn:nbn:de:101:1-2020022022113244575773
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kainuma, Takuro
- Kawakami, Shogo
- Tsumura, Hideyasu
- Satoh, Takefumi
- Tabata, Ken-ichi
- Iwamura, Masatsugu
- Hayakawa, Kazushige
- Ishiyama, Hiromichi
- SpringerLink (Online service)
Other Objects (12)
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
Phase I dose-escalation oncology trials with sequential multiple schedules
PK/PD modeling supports the dose-escalation decision in VIKING
A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)
A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
Dose escalation with stereotactic body radiotherapy for cervical cancer treatment
A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress
A dose-escalation ex vivo study on the effects of intracameral benzalkonium chloride in rabbits
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
Phase I dose-escalation oncology trials with sequential multiple schedules
PK/PD modeling supports the dose-escalation decision in VIKING
A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)
A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
Dose escalation with stereotactic body radiotherapy for cervical cancer treatment
A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress
A dose-escalation ex vivo study on the effects of intracameral benzalkonium chloride in rabbits
Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
What does a modified-Fibonacci dose-escalation actually correspond to?
Phase I dose-escalation oncology trials with sequential multiple schedules
PK/PD modeling supports the dose-escalation decision in VIKING
A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial)
A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study
Dose escalation with stereotactic body radiotherapy for cervical cancer treatment
A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma
Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial
Coenzyme Q10 dose-escalation study in hemodialysis patients: safety, tolerability, and effect on oxidative stress